Share
  • LinkedIn
  • Facebook
  • X
  • Threads

IP Whiteboard

High Court refuses special leave in innovation patent case

23 December 2009

In an update to our earlier post, the High Court has refused an application by Dura-Post for special leave to appeal from a decision of the Full Federal Court.

Dura-Post argued that the test for innovative step, laid out in section 7(4) of the Patents Act 1990, necessitated a need to assess the substance of the invention and required more than a simple functional comparison of the invention as claimed in the patent and the prior art.

Justices Gummow and Hayne refused leave stating that an appeal based on this argument would fail.

A copy of the transcript can be found here.

Share
  • LinkedIn
  • Facebook
  • X
  • Threads

More Posts From This Author

Generic supplier obtains substantial reduction in damages awarded against it

11 December 2018
Earlier this month, we reported on the Full Court’s decision in Generic Health v Bayer [2018] FCAFC 183, in which the Full Court clarified that when estimating or valuing a lost opportunity or assessing a hypothetical counterfactual for any scenario short of certainty, some discount must be made to reflect that less than certain position.  In doing so, the Full Court accepted that the trial judge, Justice Jagot, fell into error by not allowing for any such discount at first instance and proceeded to reduce the damages award by 2%.
Read on

Generic Health succeeds in invalidating patent for aripiprazole: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634

7 July 2015
Generic Health is perhaps a step closer to bringing its generic version of the antipsychotic drug aripiprazole to market in Australia after Justice Yates struck down one of Otsuka’s patents for the drug.  Although it’s unclear whether the path has been cleared for the launch of generic aripiprazole, Justice Yates’ decision – which found that key claims of the patent lacked novelty and were obvious – will be of interest to generic pharmaceutical companies faced with follow-on patents for known pharmaceutical compounds.
Read on